Quest PharmaTech Inc.

QPT

CA74836M1068

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 20:59:59 15/07/2024 BST			5-day change	1st Jan Change
0.025 ^CAD	-16.67%		0.00%	-54.55%

06-28	Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
05-30	Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	CI

Quest PharmaTech, Inc.(TSXV:QPT) added to S&P/TSX Venture Composite Index

January 18, 2016 at 05:00 am

Latest news about Quest PharmaTech Inc.

Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	06-28	CI
Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	05-30	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	05-29	CI
Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	01-30	MT
Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000	01-30	MT
Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis	01-24	MT
Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical Study	01-23	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	12-13	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	21/09/23	CI
Quest PharmaTech Provided Product Development Update	10/07/23	MT
Quest PharmaTech Inc. Provides Product Development Update	10/07/23	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	29/06/23	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	31/05/23	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	30/05/23	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	18/12/22	CI
Quest PharmaTech Details Bioceltran Interest Sale, Return of Photodynamic Therapy Technology License	28/09/22	MT
Sang Ho Jang acquired unknown minority stake in Bioceltran Co., Ltd from Quest PharmaTech Inc. for CAD 0.3 million.	27/09/22	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	26/09/22	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2022	27/06/22	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2022	26/05/22	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	25/05/22	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	23/12/21	CI
Quest Pharmatech Inc. Reports Earnings Results for the Second Quarter Ended July 31, 2021	23/09/21	CI
Quest PharmaTech Inc. Approves Appointment of J. Mark Lievonen and Jeffrey Shon as Board of Directors	07/07/21	CI
Quest Pharmatech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2021	22/06/21	CI

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.âs technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

Sector

Biotechnology & Medical Research

Calendar

18/09/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUEST PHARMATECH INC.	-54.55%	3.09M
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.38%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B